Skip to content

What are reversible inhibitors of monoamine oxidase A?

4 min read

Monoamine oxidase inhibitors (MAOIs) were among the first antidepressants developed, but their use was limited by severe dietary interactions that could lead to dangerous hypertensive crises. The development of reversible inhibitors of monoamine oxidase A (RIMAs) marked a significant advance in pharmacology, creating a safer alternative for patients requiring this therapeutic class.

Quick Summary

Reversible inhibitors of monoamine oxidase A (RIMAs) are a subclass of MAOIs that selectively and temporarily block the MAO-A enzyme, increasing neurotransmitter levels with a lower risk of hypertensive crisis.

Key Points

  • Selective and Reversible Action: RIMAs block only the MAO-A enzyme, and their binding is temporary, distinguishing them from older, irreversible MAOIs.

  • Reduced Hypertensive Risk: Unlike irreversible MAOIs, RIMAs are less likely to cause a hypertensive crisis from tyramine-rich foods because they are competitively displaced by dietary tyramine.

  • Fewer Dietary Restrictions: While caution is still advised, the dietary restrictions required for RIMAs are significantly less stringent than those necessary for patients on older, irreversible MAOIs.

  • Faster Recovery of Enzyme Function: Due to their reversible nature, MAO-A enzyme activity recovers relatively quickly after a patient stops taking a RIMA, shortening the washout period required before starting another medication.

  • Effective for Depression and Anxiety: RIMAs like moclobemide are proven effective for treating major depression, dysthymia, and anxiety disorders, sometimes used for treatment-resistant cases.

  • Potential for Serotonin Syndrome: Despite the lower risk profile, combining RIMAs with other serotonergic drugs can still lead to the serious condition of serotonin syndrome.

  • Moclobemide as a Key Example: Moclobemide is a well-known RIMA that offers a better safety and tolerability profile compared to older MAOIs.

In This Article

Understanding Monoamine Oxidase and the Role of MAO-A

Monoamine oxidase (MAO) is an enzyme responsible for breaking down monoamine neurotransmitters in the body, which include key mood-regulating chemicals like serotonin, norepinephrine, and dopamine. There are two main types of MAO enzymes: MAO-A and MAO-B. MAO-A preferentially metabolizes serotonin and norepinephrine, while MAO-B primarily breaks down other monoamines like phenylethylamine. Both types, however, can metabolize dopamine and tyramine.

By inhibiting the action of MAO-A, drugs can prevent the breakdown of these crucial neurotransmitters, leading to higher concentrations in the brain's synaptic cleft and enhancing mood. This forms the basis for their use as antidepressants.

The Reversible and Selective Mechanism of RIMAs

Older, or 'classic,' MAOIs bind irreversibly and non-selectively to both MAO-A and MAO-B enzymes. This permanent deactivation means the enzyme cannot function until new enzymes are synthesized, a process that can take up to two weeks. This mechanism leads to severe risks associated with a buildup of tyramine, a monoamine found in many aged and fermented foods, leading to a dangerous rise in blood pressure known as a hypertensive crisis.

In contrast, reversible inhibitors of monoamine oxidase A (RIMAs) utilize a different, safer mechanism:

  • Competitive Binding: RIMAs, such as moclobemide, bind reversibly and competitively to the MAO-A enzyme. This means the inhibition is temporary and the drug can be displaced from the enzyme's binding site.
  • Displacement by Tyramine: In the presence of high concentrations of tyramine from food, RIMAs can be displaced from the intestinal and hepatic MAO-A enzymes. This allows MAO-A to break down the dietary tyramine, preventing a dangerous buildup and mitigating the risk of hypertensive crisis.
  • Preservation of MAO-B: Since RIMAs are selective for MAO-A, they leave the MAO-B enzyme largely uninhibited. This provides an additional safety mechanism, as the uninhibited MAO-B can help to metabolize ingested tyramine.

Key Advantages Over Irreversible MAOIs

RIMAs offer several significant advantages over their irreversible counterparts, making them a more manageable and safer therapeutic option for many patients.

Feature Reversible MAO-A Inhibitors (RIMAs) Irreversible MAOIs
Binding Reversible; non-covalent bonding Irreversible; covalent bonding
Inhibition Temporary, concentration-dependent Permanent until new enzyme is synthesized
Selectivity Selective for MAO-A Often non-selective (inhibits both MAO-A and B)
Risk of Hypertensive Crisis Significantly lower due to competitive binding High risk due to tyramine buildup
Dietary Restrictions Less strict or unnecessary depending on dose Strict avoidance of tyramine-rich foods
Washout Period Short; effects wear off faster Long; can be weeks between therapies

Clinical Applications and Examples

RIMAs are clinically used primarily for the treatment of depressive disorders and anxiety conditions. Moclobemide is the most widely studied and representative RIMA, used for major depression, dysthymia, and social phobia. Other examples include toloxatone and brofaromine, though moclobemide is the most common example in clinical practice globally.

RIMAs have been shown to be as effective as some tricyclic antidepressants and offer a better tolerability profile. Their use is particularly beneficial for managing treatment-resistant depression where other options have been ineffective.

Important Considerations and Side Effects

While generally safer than irreversible MAOIs, RIMAs are not without potential side effects and interactions. Patients should be aware of the following:

Common Side Effects:

  • Nausea
  • Dry mouth
  • Insomnia or sleep disturbances
  • Dizziness or lightheadedness
  • Headaches
  • Restlessness

Drug Interactions and Serotonin Syndrome: RIMAs can cause serious interactions if combined with other serotonergic agents, such as selective serotonin reuptake inhibitors (SSRIs), serotonin-norepinephrine reuptake inhibitors (SNRIs), and certain opioids or herbal supplements like St. John's Wort. This can lead to serotonin syndrome, a potentially life-threatening condition characterized by confusion, rapid heart rate, high blood pressure, and muscle rigidity. A washout period is necessary when switching between these medications.

Tyramine and Hypertensive Risk: Despite the reduced risk, caution with tyramine-rich foods may still be advised, especially with higher doses or if a patient is particularly sensitive. Examples of foods to potentially monitor include:

  • Aged cheeses (aged cheddar, parmesan)
  • Cured meats (salami, sausages)
  • Fermented soy products (miso, soy sauce)
  • Certain beverages (draft beer)
  • Overripe or spoiled foods

Conclusion

Reversible inhibitors of monoamine oxidase A (RIMAs) represent a significant step forward in the treatment of depressive and anxiety disorders. By offering a selective and temporary mechanism of action, they effectively increase the levels of crucial monoamine neurotransmitters while mitigating many of the severe dietary and drug interaction risks associated with older, irreversible MAOIs. While moclobemide is the most prominent example, research continues to explore new avenues for this class of drugs, including potential roles beyond traditional psychiatric applications. The improved safety profile and predictable pharmacodynamics make RIMAs a valuable option, particularly for patients with treatment-resistant depression or those who cannot tolerate other antidepressants, though careful monitoring for drug interactions remains essential.

An excellent example of research into the pharmacodynamics of a novel RIMA, CX157, can be found in a 2009 study published by the National Institutes of Health.

Frequently Asked Questions

The main difference lies in their binding mechanism: irreversible MAOIs permanently deactivate the MAO enzyme until new enzymes are produced, which takes weeks. Reversible MAOIs, or RIMAs, bind temporarily and can be displaced from the enzyme, allowing for a faster return to normal enzyme function.

While less strict than for irreversible MAOIs, some caution is still advised. The reversible nature of RIMAs means tyramine can displace the drug, preventing buildup and significantly reducing the risk of hypertensive crisis, but some doctors may still suggest monitoring intake of highly aged or fermented foods.

The 'cheese effect' is the hypertensive crisis caused by a buildup of tyramine from aged foods, which can happen when MAO-A is irreversibly inhibited. RIMAs avoid this because their binding is reversible, meaning if high levels of dietary tyramine are encountered, the RIMA can be displaced from the enzyme, allowing MAO-A to metabolize the tyramine.

The most widely known example is moclobemide, which has been used clinically as an antidepressant. Other compounds in this class include toloxatone and brofaromine.

RIMAs increase the availability of key neurotransmitters like serotonin and norepinephrine in the brain, which are often low in individuals with depression. They are prescribed for major depressive disorder, dysthymia, and in some cases, treatment-resistant depression.

Serotonin syndrome is a potentially life-threatening reaction caused by excessive serotonin levels. It is a risk with RIMAs, especially if they are combined with other serotonergic medications such as SSRIs, certain opioids, or St. John's Wort.

RIMAs and SSRIs both increase serotonin levels, but through different mechanisms. Studies have shown RIMAs can be comparable in efficacy to some tricyclic antidepressants and are an option for treatment-resistant depression, sometimes offering better tolerability than older MAOIs.

The reversible nature of RIMAs means they detach from the MAO-A enzyme, allowing its function to recover relatively quickly. In contrast, irreversible MAOIs require the body to synthesize new enzymes, which can take weeks, necessitating a much longer washout period.

References

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10

Medical Disclaimer

This content is for informational purposes only and should not replace professional medical advice.